Spark Therapeutics Inc ONCE, a small-cap gene therapy developer that went public on January 30, is up more than 1.3 percent on Tuesday morning, after several major Wall Street research firms initiated coverage with positive ratings.
Related Link: What You Need To Know About The Spark Therapeutics IPO
Roth Capital assumed coverage with a Buy rating and a $71 price target.
Cowen & Company gave the stock an Outperform rating accompanied by a $65 price target.
Credit Suisse also issued an Outperform rating, and set its price target at $76.
Finally, JP Morgan initiated coverage with an Overweight rating and a $74 price target.
About Spark Therapeutics
Spark Therapeutics is a $1.36 billion market cap company that focuses on developing (one-time, life-altering) gene therapy products for patients suffering from debilitating genetic diseases. It addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
